Regulation of APP Processing by Par-4
Par-4 对 APP 处理的规定
基本信息
- 批准号:6767246
- 负责人:
- 金额:$ 14.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-12-01 至 2007-11-30
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer's disease amyloid proteins apoptosis calcium flux cell growth regulation enzyme linked immunosorbent assay gel electrophoresis gene targeting genetically modified animals immunoprecipitation laboratory mouse neoplastic cell culture for noncancer research neurons northern blottings polymerase chain reaction posttranslational modifications protein biosynthesis protein protein interaction protein structure protein structure function western blottings
项目摘要
DESCRIPTION (provided by applicant): We recently identified the leucine zipper protein Par-4 (prostate apoptosis response-4) as a novel cell death promoting protein associated with pathogenesis of Alzheimer's disease (AD). Importantly, we have found that Par-4 may participate in regulation of Abeta production through a caspase-dependent pathway in transfected IMR-32 cells (Guo Q. et al., Nature Medicine 1998; 4(8): 957-962, Guo Q. et al., J. Biol. Chem., 2001; 276: 16040-4). Disruption of intracellular calcium homeostasis may lead to aberrant induction of Par-4 and abnormal processing of beta amyloid precursor protein (APP). These data suggest that Par-4 may be a novel regulator of APP processing. Most recently, we found that Par-4 interacts directly with APP, and alter Abeta secretion. These data strongly indicate that Par-4 regulates APP processing by at least two different mechanisms: (a) by caspase- and calcium-dependent pathways that is activated during apoptotic process, and (b) through direct physical interaction with APP. AATF is a novel leucine zipper protein that is expressed in neurons. We found AATF binds directly to Par-4 and confers neuroprotective actions, indicating that AATF might be an endogenous regulator of Par-4 activity. The proposed studies will employ a series of in vitro and in vivo approaches to test the following hypotheses: (1) Par-4 plays an essential role in aberrant APP processing of APP after initiation of apoptotic cascades; (2) Par-4 alters APP processing during apoptosis through a calcium-dependent pathway; (3) Par-4 directly interacts with APP and alters intracellular Abeta production and/or extracellular pool of secreted APPs and Abeta under apoptotic and/or nonapoptotic conditions; (4) AATF is a novel interaction partner of Par-4 and functions as an endogenous negative regulator of Par-4 activity in APP processing. The proposed studies may establish Par-4 as a novel regulator of APP processing. Inhibition of Par-4 activity by enhancing AATF expression and/or manipulating Par-4/APP interaction may provide novel therapeutic implications for Alzheimer's disease.
描述(由申请人提供):我们最近发现亮氨酸拉链蛋白Par-4(前列腺凋亡反应-4)是一种与阿尔茨海默病(AD)发病机制相关的新型细胞死亡促进蛋白。重要的是,我们发现在转染的IMR-32细胞中,par4可能通过caspase依赖途径参与调控Abeta的产生(郭清等,Nature Medicine 1998; 4(8): 957-962)。化学。, 2001;276: 16040 - 4)。细胞内钙稳态的破坏可能导致Par-4的异常诱导和β淀粉样蛋白前体蛋白(APP)的异常加工。这些数据表明,Par-4可能是一种新的APP加工调节因子。最近,我们发现Par-4直接与APP相互作用,并改变β分泌。这些数据强烈表明,Par-4通过至少两种不同的机制调节APP加工:(a)通过凋亡过程中激活的caspase-和钙依赖性途径,以及(b)通过与APP的直接物理相互作用。AATF是一种在神经元中表达的新型亮氨酸拉链蛋白。我们发现AATF直接与Par-4结合并赋予神经保护作用,表明AATF可能是一种内源性的Par-4活性调节剂。拟开展的研究将采用一系列体外和体内方法来验证以下假设:(1)凋亡级联启动后,Par-4在APP的异常APP加工中起重要作用;(2) Par-4通过钙依赖途径改变细胞凋亡过程中APP的加工;(3)在凋亡和/或非凋亡条件下,Par-4直接与APP相互作用,改变细胞内β的产生和/或分泌的APP和β的细胞外池;(4) AATF是APP加工过程中Par-4活性的内源性负调节因子,是Par-4新的相互作用伙伴。这些研究可能会确定Par-4是APP加工的一种新的调节因子。通过增强AATF表达和/或操纵Par-4/APP相互作用抑制Par-4活性可能为阿尔茨海默病提供新的治疗意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
QING GUO其他文献
QING GUO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('QING GUO', 18)}}的其他基金
相似海外基金
Development of aggregation inhibition strategy for pathogenic amyloid proteins
致病性淀粉样蛋白聚集抑制策略的开发
- 批准号:
16H06216 - 财政年份:2016
- 资助金额:
$ 14.36万 - 项目类别:
Grant-in-Aid for Young Scientists (A)
Elucidation of the mechanisms on aggregation and toxicity of plant amyloid proteins which are toxic in the presence of metals
阐明在金属存在下有毒的植物淀粉样蛋白的聚集和毒性机制
- 批准号:
23380192 - 财政年份:2011
- 资助金额:
$ 14.36万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Demonstration of the abnormal conformational transition of amyloid proteins and it's application as an early diagnostic tool
淀粉样蛋白异常构象转变的演示及其作为早期诊断工具的应用
- 批准号:
21200072 - 财政年份:2009
- 资助金额:
$ 14.36万 - 项目类别:
Grant-in-Aid for Scientific Research on Innovative Areas (Research a proposed research project)
Metabolism of amyloid proteins and methods for detecting amyloid proteins
淀粉样蛋白的代谢和检测淀粉样蛋白的方法
- 批准号:
21790541 - 财政年份:2009
- 资助金额:
$ 14.36万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Development of aggregation disrupters for amyloid proteins
淀粉样蛋白聚集破坏剂的开发
- 批准号:
17310132 - 财政年份:2005
- 资助金额:
$ 14.36万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Inhibition of axonal transport of hippocampal neurons by amyloid proteins: relation to Alzheimer's disease
淀粉样蛋白抑制海马神经元轴突运输:与阿尔茨海默病的关系
- 批准号:
11670638 - 财政年份:1999
- 资助金额:
$ 14.36万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
RAB GTPASES AND TRAFFICKING OF BETA AMYLOID PROTEINS
RAB GTP 酶和 β 淀粉样蛋白的贩运
- 批准号:
6149928 - 财政年份:1998
- 资助金额:
$ 14.36万 - 项目类别:














{{item.name}}会员




